Special Issue

Chemoresistance in Solid Tumours

Message from the Guest Editors

Current precision medicine for solid tumours comprises a combination of appropriate cytotoxic agents and molecularly targeted drugs for each molecular subtype. Since molecular subtypes provide appropriate therapeutic targets, various molecular subtypes have been explored by gene mutation, gene expression, and protein expression. However, this tumour heterogeneity is considered one of the main reasons for chemoresistance, since refractory solid tumours exhibit high tumour heterogeneity and cannot be eliminated by several anticancer drugs. Although the cancer stem cell theory has been accepted as a model that can resolve tumour heterogeneity, tumour heterogeneity remains unresolved because cancer cells have the plasticity to revert from non-cancer stem cells to cancer stem cells. In addition, the microenvironment is one of the factors contributing to chemotherapeutic resistance in solid tumours. The prognosis for patients with highly advanced solid tumours remains poor because tumour heterogeneity, the plasticity inherent in cancer cells, and the contribution of the microenvironment to chemotherapy resistance remain unresolved.

Guest Editors

Dr. Shuva Yano

Department of Digestive Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Japan

Dr. Robert M. Hoffman

- 1. Division of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA
- 2. AntiCancer Inc., San Diego, CA 92111, USA

Deadline for manuscript submissions

closed (25 August 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/141147

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com_

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

